Estamos no ar no ! Saiba mais
ícone de ADMA

ADMA Biologics
ADMA

10,68 USD
-0,05
0,47%
No fechamento Atualizado 16 de out. 16:00 EDT
Pré-mercado
Após o fechamento do mercado
10,68
0,00
0%
1 dia
-0,47%
5 dias
3,49%
1 mês
20%
3 meses
21,23%
6 meses
-0,56%
No acumulado do ano
-40,27%
1 ano
-26,65%
5 anos
870,91%
10 anos
68,72%
 

Sobre: ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.

Funcionários: 647

Saúde Biotecnologia

Notícias

Positivo
Neutro
Negativo
Sentimento 3 meses
Positivo 2,6%
Neutro 95,4%
Negativo 2,1%
Neutro
GlobeNewsWire
ontem
ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process
Optimized Process Demonstrated Effective Removal of Procoagulant Impurities While Maintaining Immunoglobulin Quality and Increasing IgG Yield
ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process
Positivo
Zacks Investment Research
há 4 dias
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?
Neutro
Zacks Investment Research
há 8 dias
Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors
In the latest trading session, Adma Biologics (ADMA) closed at $10.33, marking a +1.87% move from the previous day.
Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors
Positivo
Zacks Investment Research
há 8 dias
ADMA Biologics Inc (ADMA) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Adma Biologics (ADMA). This makes it worthwhile to examine what the stock has in store.
ADMA Biologics Inc (ADMA) is Attracting Investor Attention: Here is What You Should Know
Negativo
Zacks Investment Research
há 17 dias
Here's Why Adma Biologics (ADMA) Fell More Than Broader Market
In the most recent trading session, Adma Biologics (ADMA) closed at $10, indicating a -1.24% shift from the previous trading day.
Here's Why Adma Biologics (ADMA) Fell More Than Broader Market
Neutro
Zacks Investment Research
há 22 dias
Why Adma Biologics (ADMA) Dipped More Than Broader Market Today
Adma Biologics (ADMA) closed at $9.52 in the latest trading session, marking a -1.86% move from the prior day.
Why Adma Biologics (ADMA) Dipped More Than Broader Market Today
Positivo
Zacks Investment Research
há 22 dias
Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It?
Positivo
Zacks Investment Research
há 28 dias
Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know
Adma Biologics (ADMA) closed the most recent trading day at $9.13, moving +2.01% from the previous trading session.
Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know
Neutro
Newsfile Corp
mês passado
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (ADMA)
Philadelphia, Pennsylvania--(Newsfile Corp. - September 14, 2026) - National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"). The investigation is focused on whether the Company engaged in channel-stuffing to drive revenue growth despite declining demand for its flagship product, ASCENIV.
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (ADMA)
Negativo
Zacks Investment Research
mês passado
Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know
Adma Biologics (ADMA) reached $9.23 at the closing of the latest trading day, reflecting a -1.7% change compared to its last close.
Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know
Ver ranking de notícias
Gráficos de preços implementados com Lightweight Charts™